Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties

Oncology Reports

Volumn 27, Issue 6, 2012, Pages 1823-1828

  Yi, Bo Rim ^a   Kim, Seung U ^b,c   Kim, Yun Bae ^a   Lee, Hong Jun ^c   Cho, Myung Haing ^d   Choi, Kyung Chul ^a  

^a Chungbuk National University   (South Korea)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Chung Ang University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Brain metastasis; Cytosine deaminase; Lung cancer; Stem cells; Tumor tropism

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CANCER LOCALIZATION; CELL DENSITY; CELL MIGRATION; CONTROLLED STUDY; CYTOSINE DEAMINASE GENE; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENETIC ENHANCEMENT; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MALE; MOUSE; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUICIDE GENE; THERAPY EFFECT; YEAST;

ANIMALS; BRAIN NEOPLASMS; CELL SURVIVAL; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GENE THERAPY; GENETIC ENGINEERING; HUMANS; LUNG NEOPLASMS; MICE; NEURAL STEM CELLS; SACCHAROMYCES CEREVISIAE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860754338     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1721     Document Type: Article

References (29)

1. Li F, Tiede B, Massague J and Kang Y: Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 17: 3-14, 2007. (Pubitemid 46096419)
2. Gavrilovic IT and Posner JB: Brain metastases: epidemiology and pathophysiology. J Neurooncol 75: 5-14, 2005. (Pubitemid 41548673)
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P and Sawaya RE: Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872, 2004. (Pubitemid 41079905)
4. Ma S, Xu Y, Deng Q and Yu X: Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer 65: 198-203, 2009.
5. Poulsen TT, Pedersen N and Poulsen HS: Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer 6: 227-236, 2005. (Pubitemid 40309333)
6. Schuette W: Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer 45 (Suppl 2): S253-S257, 2004.
7. Kim SU: Neural stem cell-based gene therapy for brain tumors. Stem Cell Rev 7: 130-140, 2010.
8. Kim KY, Kim SU, Leung PC, Jeung EB and Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci 101: 955-962, 2010.
9. Yi BR, Kang NH, Hwang KA, Kim SU, Jeung EB and Choi KC: Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res 31: 2853-2861, 2011.
10. Ramnaraine M, Pan W, Goblirsch M, Lynch C, Lewis V, Orchard P, Mantyh P and Clohisy DR: Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 63: 6847-6854, 2003. (Pubitemid 37322967)
11. Van Rite BD and Harrison RG: Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine. Cancer Lett 307: 53-61, 2011.
12. Chen JK, Hu LJ, Wang D, Lamborn KR and Deen DF: Cytosine deaminase/5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys 67: 1538-1547, 2007. (Pubitemid 46467180)
13. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, Rehemtulla A and Lawrence TS: The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model. Gene Ther 9: 844-849, 2002. (Pubitemid 34716328)
14. Tang Y, Shah K, Messerli SM, Snyder E, Breakefield X and Weissleder R: In vivo tracking of neural progenitor cell migration to glioblastomas. Hum Gene Ther 14: 1247-1254, 2003. (Pubitemid 37034574)
15. Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH, Park IH, Black PM, Carroll RS, Lee J and Kim SK: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 15: 4925-4934, 2009.
16. Yi BR, O SN, Kang NH, Hwang KA, Kim SU, Jeung EB, Kim YB, Heo GJ and Choi KC: Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. Int J Oncol 39: 833-839, 2011.
17. Carbonell WS, Ansorge O, Sibson N and Muschel R: The vascular basement membrane as 'soil' in brain metastasis. PLoS One 4: e5857, 2009.
18. Yoneda T, Williams PJ, Hiraga T, Niewolna M and Nishimura R: A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16: 1486-1495, 2001. (Pubitemid 32675200)
19. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59, 2006.
20. Nguyen DX and Massague J: Genetic determinants of cancer metastasis. Nat Rev Genet 8: 341-352, 2007. (Pubitemid 46625811)
21. van den Bent MJ: The role of chemotherapy in brain metastases. Eur J Cancer 39: 2114-2120, 2003.
22. Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, Lee SJ, Jo MY, Kim SU and Nam DH: Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 17: 570-575, 2009.
23. Hanke P, Serwe M, Dombrowski F, Sauerbruch T and Caselmann WH: DNA vaccination with AFP-encoding plasmid DNA prevents growth of subcutaneous AFP-expressing tumors and does not interfere with liver regeneration in mice. Cancer Gene Ther 9: 346-355, 2002. (Pubitemid 34289453)
24. Kim SU: Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 24: 159-171, 2004.
25. Gutova M, Najbauer J, Chen MY, Potter PM, Kim SU and Aboody KS: Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme. Curr Stem Cell Res Ther 5: 273-276, 2010.
26. Seol HJ, Jin J, Seong DH, Joo KM, Kang W, Yang H, Kim J, Shin CS, Kim Y, Kim KH, et al: Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Lett 311: 152-159, 2011.
27. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM and Redinbo MR: Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 9: 337-342, 2002. (Pubitemid 34462550)
28. Aboody KS, Najbauer J and Danks MK: Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15: 739-752, 2008. (Pubitemid 351627357)
29. Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, et al: Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 26: 1406-1413, 2008.